Share on

Asia Pacific Biosimilars Market Research Report – Segmented By Type, Technology, Application and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 1081
Pages: 145
Formats: report pdf report excel report power bi report ppt

APAC Biosimilars Market Size (2023 to 2028)

As per our analysis, the biosimilars market size in the Asia Pacific is predicted to grow from 1.65 billion in 2023. This value is predicted to grow to USD 6.54 billion by 2028 and at a CAGR of 31.60% during the forecast period.

Biosimilars are recognized as among the healthcare industry's most important markets and are seen as an accessible and economical treatment option with rising healthcare costs. Growing economies are seeing extensive development from the challenging medical therapeutic needs in the biosimilar industry. Increasing GDP and healthcare sector spending and demand for an economical therapeutic solution have contributed to this market's growth. Besides, biosimilars find their use in preventing and treating various chronic disorders like diabetes, cancers, cardiovascular diseases, etc. The demand for biosimilars is likely to rise in the coming years.

While Asia-Pacific is the quickest-growing market for biosimilars due to low production costs, skilled and cheap labor availability, slender regulations laid down by governments, there are, however, cost high for manufacturing and sophistication, and the prevalence on the market of economically priced generic drugs, which has come forward as some of the biosimilars market's main constraints.

Biosimilars are a great opportunity; the market will eventually become a large business, irrespective of a slow start. Countries like India, China, and South Korea are providing an enticing opportunity to develop and sell medicines in the region. Besides, these markets are generic-driven, creating a favorable incentive for the development and marketing of biosimilars. Also, the growing initiatives from the government and increasing investment in the healthcare sector in the region are providing lucrative growth opportunities for the region’s market to grow substantially. Large profit-churning blockbuster drugs are expected to lose their patent protection in APAC throughout the forecast period, and biosimilar firms are vigilant in filing marketing rights proposals.

This research report on the APAC Biosimilars Market has been segmented and sub-segmented market into the following categories:

By Product Type:

  • Protein
  • Insulin
  • Human Growth Hormones
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon

By Technology:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic resonance (NMR) technology
  • Electrophoresis
  • Bioassay

By Disease:

  • Oncology Diseases
  • Blood Disorders
  • Growth hormone deficiencies
  • Chronic and autoimmune diseases
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The market for biosimilars in Asian nations is projected to develop significantly in the near future because of the readily available skilled labor, cheaper production costs, and fewer regulatory requirements. China, India, and Korea are all seeing active expansion in the biosimilars industry right now. Biosimilars provide rising Asian nations a significant opportunity to develop indigenous biologics and biotechnology capabilities. Domestic and regional biosimilar producers in Asian developing markets will be able to take the worldwide leader in the near future. Because the number of biosimilar producers in China is rapidly increasing, the Chinese FDA has established and approved biosimilars standards governing China's production, sale, and consumption. The primary drivers driving the market expansion in this area are the rising frequency of chronic diseases such as malignancies and increased investment in research and development efforts by key companies. Chronic diseases such as diabetes, cancer, and rheumatoid arthritis are becoming more common throughout the world, necessitating an ever-increasing demand for biologicals that are inexpensive and accessible in Asia Pacific countries (APAC).

Biosimilars are growing in APAC, and several biotech companies have either opened or are in the process of constructing production facilities to deliver inexpensive medicines to Asian patients. In the research and marketing of biosimilars, China and India are also regarded to be prominent nations. While this type of product has been on the market for decades, the necessary rules and regulations have recently been adopted. The Chinese government has a variety of programs in place to help with biosimilar development and uptake. These include establishing transnational clinical centers, exchanging clinical data globally, expediting the special medication approval procedure, and improving clinical data security. The region's market growth is boosted by an expanding product pipeline and new product releases.


A few notable companies operating in the APAC Biosimilars market are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics, and Cipla Ltd.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample